ifosfamide has been researched along with Prostatic Neoplasms in 47 studies
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC." | 7.78 | Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide. ( Hayashi, T; Matsuoka, K; Nishihara, K; Tomiyasu, K; Uemura, K, 2012) |
| "Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP)." | 7.67 | [Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)]. ( Ebisui, K; Fujiwara, M; Kobayashi, T; Miyakoda, K; Nakagawa, S; Nakao, M; Nukui, M; Takada, H; Toyoda, K; Watanabe, H, 1989) |
| "Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog." | 5.27 | [Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983) |
| " We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC." | 3.78 | Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide. ( Hayashi, T; Matsuoka, K; Nishihara, K; Tomiyasu, K; Uemura, K, 2012) |
| "Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil." | 3.67 | [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987) |
| "Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP)." | 3.67 | [Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)]. ( Ebisui, K; Fujiwara, M; Kobayashi, T; Miyakoda, K; Nakagawa, S; Nakao, M; Nukui, M; Takada, H; Toyoda, K; Watanabe, H, 1989) |
| "Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i." | 3.67 | [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989) |
| " The optimal sequence of chemotherapeutic agents was investigated by reversing the order of administration in the second cycle and by collecting a total of six pharmacokinetic blood samples per cycle from all patients during the first and second cycles." | 2.71 | Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study. ( Hervonen, P; Jekunen, A; Kellokumpu-Lehtinen, P; Lefebvre, P, 2003) |
| "The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997) |
| "Prostate cancer, bladder cancer, renal cancer and testicular cancer are common among urological cancers." | 2.41 | [Chemotherapy and radiotherapy for urological cancer]. ( Akaza, H; Hattori, K; Kawai, K; Miyanaga, N; Shimazui, T; Tsukamoto, S; Uchida, K, 2002) |
| "Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1." | 2.40 | [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. ( Asahi, T; Hata, K; Katayama, Y; Kobashi, K; Kobuke, M; Kondo, K; Kumon, H; Maki, Y; Nanba, K; Nasu, Y; Ochi, J; Ohashi, T; Ohmori, H; Ozaki, Y; Saegusa, M; Saika, T; Tanahashi, T; Tsushima, T; Uno, S; Yamashita, Y, 1998) |
| "The spindle cell rhabdomyosarcoma is a rare variant of the embryonal rhabdomyosarcoma, mostly occurring in childhood." | 1.39 | Spindle cell rhabdomyosarcoma of the prostate. ( Ellinger, J; Fechner, G; Goltz, D; Latz, S; Leuschner, I; Marx, C; Müller, SC, 2013) |
| "The patient died due to brain metastases 20 months after the start of intra-arterial chemotherapy." | 1.30 | [A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port]. ( Hasegawa, N; Kazama, A; Kondo, N; Tomita, M, 1999) |
| "The patients with prostatic cancer were treated with VIP (vincristine, ifosfamide, peplomycin) chemotherapy and the patients with urothelial cancer were treated with MP (methotrexate, cisplatinum) or MEP (methotrexate, Etoposide, cisplatinum) combination chemotherapy." | 1.29 | [Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer]. ( Kitamura, Y; Komatsubara, S; Sakata, Y; Watanabe, M, 1993) |
| " After dosing with the D-compound, the highest levels of radioactivity were found in the liver, kidneys, thymus, thyroid gland, and central nervous system, including the brain." | 1.29 | Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. ( Bertram, B; Bollow, U; Hull, WE; Pohl, J; Port, R; Schaper, M; Stüben, J; Wiessler, M, 1996) |
| "Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog." | 1.27 | [Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983) |
| "Treatment with ifosfamide or combination chemotherapy with vincristine, ifosfamide and peplomycin was performed in some of the 65 cases above mentioned." | 1.27 | [Reactivation of prostatic cancer and chemotherapy in reactivated prostatic cancer]. ( Ando, K; Fuse, H; Hara, S; Shimazaki, J; Zama, S, 1985) |
| "Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy)." | 1.27 | [Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer]. ( Akiya, T; Katayama, T; Kazama, T; Nakada, T; Umeda, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (31.91) | 18.7374 |
| 1990's | 16 (34.04) | 18.2507 |
| 2000's | 11 (23.40) | 29.6817 |
| 2010's | 4 (8.51) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Findlay, BL | 1 |
| Gargollo, PC | 1 |
| Granberg, CF | 1 |
| Xing, PY | 1 |
| Shi, YK | 1 |
| Feng, FY | 1 |
| Qin, Y | 1 |
| Liu, P | 1 |
| Uemura, K | 1 |
| Nishihara, K | 1 |
| Hayashi, T | 1 |
| Tomiyasu, K | 1 |
| Matsuoka, K | 1 |
| Hervonen, P | 3 |
| Tulijoki, T | 1 |
| Kellokumpu-Lehtinen, P | 3 |
| Latz, S | 1 |
| Ellinger, J | 1 |
| Goltz, D | 1 |
| Marx, C | 1 |
| Leuschner, I | 1 |
| Müller, SC | 1 |
| Fechner, G | 1 |
| Lehtinen, T | 1 |
| Tammela, TL | 1 |
| Lam, KC | 1 |
| Yeo, W | 1 |
| Shirakawa, T | 1 |
| Fujisawa, M | 1 |
| Gotoh, A | 1 |
| Okada, H | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Jekunen, A | 1 |
| Lefebvre, P | 1 |
| Watanabe, A | 1 |
| Taniguchi, M | 1 |
| Saito, T | 1 |
| Kitamura, Y | 2 |
| Komatsubara, S | 2 |
| Kaku, H | 1 |
| Saika, T | 2 |
| Tsushima, T | 5 |
| Nagai, A | 1 |
| Yokoyama, T | 1 |
| Abarzua, F | 1 |
| Ebara, S | 1 |
| Manabe, D | 1 |
| Nasu, Y | 3 |
| Kumon, H | 3 |
| Csomor, J | 1 |
| Kaszás, I | 1 |
| Kollár, B | 1 |
| Pajor, L | 1 |
| Egyházi, Z | 1 |
| Fekete, S | 1 |
| Egyed, M | 1 |
| Timár, B | 1 |
| Kawai, T | 2 |
| Takeda, T | 1 |
| Kihara, K | 3 |
| Sakuramoto, T | 1 |
| Satomi, Y | 1 |
| Akimoto, S | 1 |
| Ohki, T | 1 |
| Akakura, K | 1 |
| Masai, M | 1 |
| Shimazaki, J | 2 |
| Watanabe, M | 1 |
| Sakata, Y | 1 |
| Ushiyama, T | 1 |
| Ihara, H | 1 |
| Kurita, Y | 1 |
| Kageyama, S | 1 |
| Ueda, D | 1 |
| Mugiya, S | 1 |
| Yamaguchi, Y | 1 |
| Nakano, M | 2 |
| Suzuki, K | 1 |
| Kawabe, K | 1 |
| Fujita, K | 1 |
| Matsushima, H | 1 |
| Kaneko, T | 1 |
| Palmer, MA | 1 |
| Viswanath, S | 1 |
| Desmond, AD | 1 |
| Stüben, J | 1 |
| Port, R | 1 |
| Bertram, B | 1 |
| Bollow, U | 1 |
| Hull, WE | 1 |
| Schaper, M | 1 |
| Pohl, J | 1 |
| Wiessler, M | 2 |
| Williamson, SK | 1 |
| Wolf, MK | 1 |
| Eisenberger, MA | 1 |
| O'Rourke, MA | 1 |
| Brannon, W | 1 |
| Crawford, ED | 1 |
| Ashraf, MS | 1 |
| Skinner, R | 1 |
| English, MW | 1 |
| Craft, AW | 1 |
| Pearson, AD | 1 |
| Tsumatani, K | 1 |
| Ozono, S | 1 |
| Momose, H | 1 |
| Hirao, Y | 1 |
| Okajima, E | 1 |
| Kaneko, Y | 1 |
| Watanabe, S | 1 |
| Samma, S | 1 |
| Yamada, K | 1 |
| Palackdharry, CS | 1 |
| Haberkorn, U | 1 |
| Krems, B | 1 |
| Gerlach, L | 1 |
| Bachert, P | 1 |
| Morr, I | 1 |
| van Kaick, G | 1 |
| Maki, Y | 1 |
| Ohmori, H | 2 |
| Tanahashi, T | 2 |
| Nanba, K | 2 |
| Ohashi, T | 1 |
| Kondo, K | 1 |
| Asahi, T | 1 |
| Saegusa, M | 2 |
| Ozaki, Y | 3 |
| Yamashita, Y | 1 |
| Katayama, Y | 1 |
| Kobuke, M | 1 |
| Uno, S | 1 |
| Ochi, J | 2 |
| Kobashi, K | 1 |
| Hata, K | 1 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Yoshida, T | 1 |
| Yonese, J | 1 |
| Izutami, T | 1 |
| Fukui, I | 3 |
| Ishikawa, Y | 1 |
| Kondo, N | 1 |
| Tomita, M | 1 |
| Hasegawa, N | 1 |
| Kazama, A | 1 |
| De Raeve, H | 1 |
| Jeuris, W | 1 |
| Wyndaele, JJ | 1 |
| Van Marck, E | 1 |
| Miyanaga, N | 1 |
| Tsukamoto, S | 1 |
| Hattori, K | 1 |
| Kawai, K | 1 |
| Shimazui, T | 1 |
| Uchida, K | 1 |
| Akaza, H | 1 |
| Maeda, O | 1 |
| Saiki, S | 1 |
| Kinouchi, T | 1 |
| Kuroda, M | 1 |
| Miki, T | 1 |
| Usami, M | 1 |
| Kotake, T | 1 |
| Mahjoubi, M | 1 |
| Azab, M | 1 |
| Ghosn, M | 1 |
| Theodore, C | 1 |
| Droz, JP | 1 |
| Yoshimoto, J | 2 |
| Akagi, T | 2 |
| Obama, T | 2 |
| Matsumura, Y | 1 |
| Fuse, H | 1 |
| Ando, K | 1 |
| Hara, S | 1 |
| Zama, S | 1 |
| Kazama, T | 1 |
| Katayama, T | 1 |
| Umeda, K | 1 |
| Akiya, T | 1 |
| Nakada, T | 1 |
| Hara, M | 1 |
| Moriyama-Gonda, N | 2 |
| Kishi, H | 1 |
| Himeno, Y | 1 |
| Ishibe, T | 3 |
| Mizutani, M | 1 |
| Ehara, S | 1 |
| Usui, T | 2 |
| Nukui, M | 1 |
| Nakao, M | 1 |
| Nakagawa, S | 1 |
| Toyoda, K | 1 |
| Takada, H | 1 |
| Ebisui, K | 1 |
| Watanabe, H | 1 |
| Miyakoda, K | 1 |
| Kobayashi, T | 1 |
| Fujiwara, M | 1 |
| Nightingale, SL | 1 |
| Dunzendorfer, U | 1 |
| Takeuchi, S | 2 |
| Higashi, Y | 2 |
| Andoh, M | 1 |
| Kitahara, S | 2 |
| Horiuchi, S | 1 |
| Oshima, H | 2 |
| Tsukagoshi, S | 1 |
| Negishi, T | 1 |
| Hosoda, K | 1 |
| Ikegami, S | 1 |
| Moriyama, N | 1 |
| Nagafuji, T | 1 |
| Ohsumi, Y | 1 |
| Brock, N | 1 |
6 reviews available for ifosfamide and Prostatic Neoplasms
| Article | Year |
|---|---|
[Clinical characteristics and treatment of desmoplastic small round cell tumor].
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2010 |
[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
[Chemotherapy for prostate cancer].
Topics: Antineoplastic Agents; Cisplatin; Estramustine; Humans; Ifosfamide; Male; Peplomycin; Prostatic Neop | 2000 |
Cystosarcoma phyllodes of the prostate with rhabdomyoblastic differentiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fatal | 2001 |
[Chemotherapy and radiotherapy for urological cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Administrati | 2002 |
11 trials available for ifosfamide and Prostatic Neoplasms
| Article | Year |
|---|---|
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Ifosfami | 2012 |
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease Progression; Dose-R | 2002 |
Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Ifosfamide; Mal | 2003 |
Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Chemotherapy for endocrine-therapy-refractory prostate cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1994 |
[Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Admin | 1993 |
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
[Clinical study of testicular cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combi | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carci | 1997 |
Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.
Topics: Aged; Drug Administration Schedule; Humans; Ifosfamide; Male; Mesna; Middle Aged; Prostatic Neoplasm | 1990 |
[A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1988 |
30 other studies available for ifosfamide and Prostatic Neoplasms
| Article | Year |
|---|---|
Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pediatric Sarcoma for Maximal Oncologic Control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cystectomy; Cytoreducti | 2020 |
Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamide; Infusions, Intra-Arte | 2012 |
Spindle cell rhabdomyosarcoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Humans; Ifosfamide; Magne | 2013 |
Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Lung Neoplas | 2002 |
Complete resection of synovial sarcoma of prostatic fascia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam | 2003 |
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2005 |
[Chemo-endocrine therapy for newly diagnosed stage D2 prostate cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etopo | 2005 |
Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].
Topics: Aged; Cyclophosphamide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metast | 1983 |
[Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer].
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherap | 1993 |
[Ifosfamide in combined hormonochemotherapy on prostate cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
Adult prostatic rhabdomyosarcoma.
Topics: Adult; Combined Modality Therapy; Humans; Ifosfamide; Male; Prostatectomy; Prostatic Neoplasms; Rhab | 1993 |
Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
Topics: Animals; Antineoplastic Agents; Autoradiography; Bile; DNA, Neoplasm; Female; Glucose; Half-Life; Hu | 1996 |
Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.
Topics: Antineoplastic Agents, Alkylating; Child, Preschool; Chronic Disease; Fanconi Syndrome; Glomerular F | 1997 |
Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Drug Monitoring; Drug Screening Assays, | 1998 |
[A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasm | 1999 |
[Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Admini | 1991 |
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with advanced stage D adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Humans; | 1985 |
[Reactivation of prostatic cancer and chemotherapy in reactivated prostatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Humans; Ifosfamid | 1985 |
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Hu | 1986 |
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A | 1987 |
[Inhibitory effect of various combinations of peplomycin, vincristine and ifosfamide against a hormone-independent human prostatic carcinoma cell line].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Cell Line; Cell Survival; | 1988 |
Inhibitory effects of vincristine, ifosfamide and peplomycin on hormone-independent human prostatic carcinoma cell line.
Topics: Bleomycin; Cell Division; Cell Line; Drug Combinations; Humans; Ifosfamide; Male; Peplomycin; Prosta | 1988 |
[Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1989 |
From the Food and Drug Administration.
Topics: Acyclovir; Anilides; Cytomegalovirus Infections; Flutamide; Ganciclovir; Humans; Ifosfamide; Male; M | 1989 |
Hormonal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diethylstilbestrol; Epiru | 1989 |
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human | 1989 |
[Ifomide].
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Leukemia, Experimental; | 1987 |
[Study of anti-cancer chemotherapy of prostatic carcinoma. I. Comparative study of ifosfamide and VIP against a hormone-independent human prostatic carcinoma cell line].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cells, Cultured; Cisplatin; Humans; I | 1987 |
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.
Topics: Alkylating Agents; Antineoplastic Agents; Biotransformation; Cyclophosphamide; Female; Humans; Ifosf | 1986 |